Attenuated Inflammatory Response in Lap… | Clinical Trial

Key information

Conditions

Regulation of Inflammatory Response Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Oslo University Hospital

Oslo, 0407, Norway

About this study

Blood samples from 20 patient with colon cancer collected before and in 3 days following laparoscopic surgery. Analyzed for inflammatory cytokines and corresponding SOCS3 mRNA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Colon cancer stage I-III -

Exclusion criteria

Colon cancer stage IV

-

Treatment and study plan

Laparoscopic resection

Procedure

Inflammatory response in laparoscopic surgery

Other names: Colon cancer

Primary outcomes

Inflammatory values for laparoscopic resection for colon cancer.

Time frame: 3 days

Corresponding values of SOCS3 mRNA copared to inflammatory cytokines in patients with laparoscopic resection for colon cancer.

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Registry information

Official study title

Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery

Important dates

Study start: 2007
Primary completion: 2011
Study completion: 2011
First posted: Aug 18, 2011
Registry last updated: Dec 16, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed